Pre-earnings options volume in Crispr Therapeutics is normal with calls leading puts 19:5. Implied volatility suggests the market is anticipating a move near 7.4%, or $3.65, after results are released. Median move over the past eight quarters is 4.4%.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Vertex Pharmaceuticals (NASDAQ:VRTX) Slides despite Raising Revenue Guidance
- CRSP Earnings this Week: How Will it Perform?
- JMP Securities healthcare analysts hold an analyst/industry conference call
- CRISPR Therapeutics Nears 52-Week Low. Time to Buy?
- Crispr Therapeutics call volume above normal and directionally bullish